Effectiveness of Liver Metastasectomies in Patients With Metastatic Colorectal Cancer Treated With FIr-B/FOx Triplet Chemotherapy Plus Bevacizumab

Micro-Abstract Effectiveness of intensive medical treatment and secondary liver surgery was evaluated in 50 patients with metastatic colorectal cancer treated with the FIr-B/FOx (triplet chemotherapy plus bevacizumab) regimen. Liver metastasectomies were performed in 26% overall and 54% of patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical colorectal cancer 2012-06, Vol.11 (2), p.119-126
Hauptverfasser:	Bruera, Gemma, Cannita, Katia, Giuliante, Felice, Baldi, Paola Lanfiuti, Vicentini, Roberto, Marchetti, Paolo, Nuzzo, Gennaro, Antonucci, Adelmo, Ficorella, Corrado, Ricevuto, Enrico
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - surgery Aged Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Camptothecin - administration & dosage Camptothecin - analogs & derivatives Colonic Neoplasms - drug therapy Colonic Neoplasms - pathology Colonic Neoplasms - surgery Combined Modality Therapy Disease-Free Survival Female Fluorouracil - administration & dosage Gastroenterology and Hepatology Hematology, Oncology and Palliative Medicine Hepatectomy Humans Integrated treatments Intensive chemotherapy Liver limited Liver Neoplasms - mortality Liver Neoplasms - secondary Liver Neoplasms - surgery Liver only Liver surgery Male Metastasectomy - methods Middle Aged Organoplatinum Compounds - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract Effectiveness of intensive medical treatment and secondary liver surgery was evaluated in 50 patients with metastatic colorectal cancer treated with the FIr-B/FOx (triplet chemotherapy plus bevacizumab) regimen. Liver metastasectomies were performed in 26% overall and 54% of patients with liver-only metastases. Integrated treatments significantly improved the clinical outcome of patients with metastatic colorectal cancer with liver-only metastases (progression-free survival, 17 months; overall survival, 44 months) compared with multiple metastatic sites and single compared with multiple liver metastases.
ISSN:	1533-0028 1938-0674
DOI:	10.1016/j.clcc.2011.11.002